Prospective study of first stroke in relation to plasma homocysteine and MTHFR 677C>T and 1298A>C genotypes and haplotypes - Evidence for an association with hemorrhagic stroke

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 9, 2011, Pages 1555-1562

  Hultdin, Johan ^a   Van Guelpen, Bethany ^a   Winkvist, Anna ^b   Hallmans, Göran ^a   Weinehall, Lars ^a   Stegmayr, Birgitta ^a   Nilsson, Torbjörn K ^c  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cerebral hemorrhage; Homocysteine; MTHFR; Risk factors; Stroke

Indexed keywords

HOMOCYSTEINE;

ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; BODY MASS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; SWEDEN;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEMORRHAGE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STROKE;

EID: 80052834812     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.234     Document Type: Article

References (50)

1. HomocysteineStudiesCollaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J Am Med Assoc 2002;288:2015-22.
2. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a metaanalysis of prospective cohort studies. J Clin Epidemiol 2002; 55:882-7. (Pubitemid 35246558)
3. Clarke R, Lewington S, Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int 2003; 63(Suppl 84):S131-3. (Pubitemid 36513394)
4. Fallon UB, Ben-Shlomo Y. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a metaanalysis. Neurology 2003;60:526-7. (Pubitemid 36188267)
5. Møller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jørgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 2000;60: 491-9.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
7. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529-36. (Pubitemid 34919985)
8. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. J Am Med Assoc 2004; 291:565-75. (Pubitemid 38500310)
9. Bønaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354:1578-88.
10. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
11. The VITATOPS trial study group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9:855-65.
12. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, et al. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-43.
13. Hankey GJ, Eikelboom JW. Folic acid-based multivitamin therapy to prevent stroke: the jury is still out. Stroke 2004;35: 1995-8. (Pubitemid 38971890)
14. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
15. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998;62:1044-51. (Pubitemid 28199004)
16. Brilakis ES, Berger PB, Ballman KV, Rozen R. Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid. Atherosclerosis 2003;168:315-22. (Pubitemid 36703331)
17. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 2001;1:189-201.
18. Spotila LD, Jacques PF, Berger PB, Ballman KV, Ellison RC, Rozen R. Age dependence of the influence of methylenetetrahydrofolate reductase genotype on plasma homocysteine level. Am J Epidemiol 2003;158:871-7. (Pubitemid 37323249)
19. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, et al. Elevatedplasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. Stroke 2003;34: 2085-90. (Pubitemid 37099816)
20. Boysen G, Brander T, Christensen H, Gideon R, Truelsen T. Homocysteine and risk of recurrent stroke. Stroke 2003;34: 1258-61. (Pubitemid 36547525)
21. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44. (Pubitemid 29044117)
22. Van Guelpen B, Hultdin J, Johansson I, Stegmayr B, Hallmans G, Nilsson TK, et al. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake. Stroke 2005; 36:1426-31. (Pubitemid 40967506)
23. Weinehall L, Hallgren CG, Westman G, Janlert U, Wall S. Reduction of selection bias in primary prevention of cardiovascular disease through involvement of primary health care. Scand J Prim Health Care 1998;16:171-6. (Pubitemid 28459674)
24. Stegmayr B, Lundberg V, Asplund K. The events registration and survey procedures in the Northern Sweden MONICA Project. Scand J Public Health Suppl 2003;61:9-17.
25. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72. (Pubitemid 28453294)
26. Iso H, Moriyama Y, Sato S, Kitamura A, Tanigawa T, Yamagishi K, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation 2004;109: 2766-72. (Pubitemid 38737924)
27. Peck G, Smeeth L, Whittaker J, Casas JP, Hingorani A, Sharma P. The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults. PLoS ONE 2007;3:e3691.
28. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, et al. Methylenetetrahydrofolate reductase gene polymorphism. Relation to blood pressure and cerebrovascular disease. Am J Hypertens 1998;11:1019-23. (Pubitemid 28378417)
29. Fang X, Namba H, Akamine S, Sugiyama K. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. Neurol Res 2005;27:73-6. (Pubitemid 40189609)
30. Sazci A, Ergul E, Tuncer N, Akpinar G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: dual effect of MTHFR polymorphisms C677T and A1298C. Brain Res Bull 2006; 71:45-50. (Pubitemid 44750419)
31. Dikmen M, Ozbabalik D, Gunes HV, Degirmenci I, Bal C, Ozdemir G, et al. Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurol Scand 2006;113:307-14.
32. Stegmann K, Ziegler A, Ngo ET, Kohlschmidt N, Schroter B, Ermert A, et al. Linkage disequilibrium of MTHFR genotypes 677C/T-1298A/C in the German population and association studies in probands with neural tube defects (NTD). Am J Med Genet 1999;87:23-9. (Pubitemid 29522057)
33. Mu LN, Cao W, Zhang ZF, Cai L, Jiang QW, You NC, et al. Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and the risk of primary hepatocellular carcinoma (HCC) in a Chinese population. Cancer Causes Control 2007;18:665-75. (Pubitemid 46883684)
34. Ulvik A, Ueland PM, Fredriksen A, Meyer K, Vollset SE, Hoff G, et al. Functional interference of the methylenetetrahydrofolate reductase 677C)T and 1298A)C polymorphisms from a large-scale epidemiological study. Hum Genet 2007;121:57-64. (Pubitemid 46421141)
35. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
36. Kristensen B, Malm J, Nilsson TK, Hultdin J, Carlberg B, Dahlén G, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. Stroke 1999;30:974-80. (Pubitemid 29211613)
37. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9-19. (Pubitemid 24103795)
38. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ, et al. A prospective study of plasma homocyst( e)ine and risk of ischemic stroke. Stroke 1994;25:1924-30. (Pubitemid 24291274)
39. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 2004;104:3046-51. (Pubitemid 39507118)
40. Zee RY, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, et al. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem 2007;53:845-51. (Pubitemid 46744239)
41. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003;34:632-6. (Pubitemid 36307383)
42. Dickinson CJ. Genetics of stroke. Lancet 2004;364:581.
43. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. Homocysteine and essential hypertension. J Clin Pharmacol 2003;43:1299-1306. (Pubitemid 37433302)
44. Stuhlinger MC, Stanger O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab 2005;6:3-14. (Pubitemid 40277876)
45. Okumura K, Aso Y. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy. Metabolism 2003;52:1517-22. (Pubitemid 37461125)
46. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmans G. Prospective study on soluble thrombomodulin and von Willebrand factor and the risk of ischemic and hemorrhagic stroke. Thromb Haemost 2002;87:211-7. (Pubitemid 34139855)
47. Macko RF, Kittner SJ, Ivey FM, Epstein A, Sparks MJ, Hebel JR, et al. Effects of vitamin therapy on plasma total homocysteine, endothelial injury markers, and fibrinolysis in stroke patients. J Stroke Cerebrovasc Dis 2002;11:1-8. (Pubitemid 34761177)
48. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. J Am Med Assoc 2006;296:2720-6. (Pubitemid 44917549)
49. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a metaanalysis. Lancet 2007;369:1876-82. (Pubitemid 46829358)
50. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JA, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37485 individuals. Arch Intern Med 2010;170:1622-31.